NCT05788965View on ClinicalTrials.gov

Semaglutide in CFRD

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Cystic FibrosisCystic Fibrosis-related Diabetes

Interventions

DRUG

Semaglutide

glucagon-like peptide 1 (GLP-1) receptor agonist

Trial Locations (1)

55455

University of Minnesota, Minneapolis

All Listed Sponsors

collaborator

Cystic Fibrosis Foundation

OTHER

lead

University of Minnesota

OTHER